阿帕贝隆对肾脏疾病患者血浆蛋白的益处
本研究纳入4或5期慢性肾脏病患者及匹配对照,单次给予阿帕贝隆后采用SOMAscan 1.3k平台进行血浆蛋白质组学分析。基线时肾病患者的169种血浆蛋白存在差异富集,涉及42条通路激活;给药后12小时,阿帕贝隆可抑制这些通路并降低IL-6、PAI-1和骨桥蛋白等疾病标志物水平。
要点
- 肾病患者基线有169种血浆蛋白差异表达,涉及免疫炎症、氧化应激等42条通路。
- 单次阿帕贝隆给药12小时后可抑制肾病相关通路活化并降低多种疾病标志物。
- 阿帕贝隆对CKD及其心血管并发症相关通路具有有益影响。
核心结论
- 肾损伤患者存在血浆蛋白质组失调,阿帕贝隆可有益地影响与慢性肾脏病及其心血管并发症相关的通路。
研究设计与样本
- 4期或5期慢性肾脏病患者与匹配对照接受单次阿帕贝隆给药,采集血浆进行药代动力学分析和SOMAscan 1.3k平台蛋白质组学检测。
主要发现
- 基线时肾病患者与对照相比有169种血浆蛋白差异富集(校正P值<0.05),包括胱抑素C和β2微球蛋白。
- 生物信息学分析显示42条控制免疫与炎症、氧化应激、内皮功能障碍、血管钙化和凝血的通路显著激活。
- 给药后12小时,阿帕贝隆抑制了与肾病相关的通路激活,并降低了白介素-6、纤溶酶原激活物抑制剂-1和骨桥蛋白等疾病标志物的丰度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Apabetalone, a small molecule inhibitor, targets epigenetic readers termed BET proteins that contribute to gene dysregulation in human disorders. Apabetalone has in vitro and in vivo anti-inflammatory and antiatherosclerotic properties. In phase 2 clinical trials, this drug reduced the incidence of major adverse cardiac events in patients with cardiovascular disease. Chronic kidney disease is associated with a progressive loss of renal function and a high risk of cardiovascular disease. We studied the impact of apabetalone on the plasma proteome in patients with impaired kidney function. METHODS: Subjects with stage 4 or 5 chronic kidney disease and matched controls received a single dose of apabetalone. Plasma was collected for pharmacokinetic analysis and for proteomics profiling using the SOMAscan 1.3k platform. Proteomics data were analyzed with Ingenuity Pathway Analysis to identify dysregulated pathways in diseased patients, which were targeted by apabetalone. RESULTS: At baseline, 169 plasma proteins (adjusted P value <0.05) were differentially enriched in renally impaired patients versus control subjects, including cystatin C and β2 microglobulin, which correlate with renal function. Bioinformatics analysis of the plasma proteome revealed a significant activation of 42 pathways that control immunity and inflammation, oxidative stress, endothelial dysfunction, vascular calcification, and coagulation. At 12 hours postdose, apabetalone countered the activation of pathways associated with renal disease and reduced the abundance of disease markers, including interleukin-6, plasminogen activator inhibitor-1, and osteopontin. CONCLUSION: These data demonstrated plasma proteome dysregulation in renally impaired patients and the beneficial impact of apabetalone on pathways linked to chronic kidney disease and its cardiovascular complications.
引用
- Wasiak S, Tsujikawa LM, Halliday C, et al. Benefit of Apabetalone on Plasma Proteins in Renal Disease. Kidney Int Rep. 2017. PMID: 29854980. doi:10.1016/j.ekir.2017.12.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。